CIA
HAE icon

CSat Investment Advisory’s Haemonetics HAE Stock Holding History

CSat Investment Advisory’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-370
Closed -$32K – 708
2020
Q3 		$32K Buy
370
+48
+15% +$4.2K ﹤0.01% 750
2020
Q2 		$29K Buy
322
+210
+188% +$21.2K ﹤0.01% 754
2020
Q1 		$11K Buy
112
+23
+26% +$2.49K ﹤0.01% 885
2019
Q4 		$10K Sell
89
-1,368
-94% -$166K ﹤0.01% 984
2019
Q3 		$184K Buy
1,457
+269
+23% +$34.1K 0.06% 216
2019
Q2 		$143K Buy
+1,188
New +$117K 0.05% 234

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CSat Investment Advisory's HAE Position: Q4 2020 in Review

CSat Investment Advisory sold out of Haemonetics (HAE) in Q4 2020, closing a stake of 370 shares — an estimated $32K sold.

CSat Investment Advisory first reported a position in HAE in Q2 2019 and held it in 6 quarters. The position peaked at $184K in Q3 2019. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

  • CSat Investment Advisory reported no remaining Haemonetics position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 370 Haemonetics shares in Q4 2020, an estimated $32K.
  • CSat Investment Advisory first reported a position in Haemonetics in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Haemonetics position peaked at $184K in Q3 2019.
  • 286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.